# US 2020/0392222 A1 · Il-18 binding protein (il-18bp) in inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392222 A1
- Document ID: US20200392222A1
- Status: Published application
- Kind: A1
- Application number: 16/883,735
- Filed: 2020-05-26
- Published: 2020-12-17
- Earliest claimed: 2013-09-05
- Assignees: AB2 Bio SA
- Applicants: AB2 Bio SA
- Inventors: Andrea PFEIFER; Greg DEL VAL
- Web page: https://patentgrep.com/patent/US20200392222A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/54: Interleukins [IL]
- C07K 14/7155: {for interleukins [IL]}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6869: {Interleukin}
- A61K 2039/505: {comprising antibodies}
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/54: Interleukins [IL]
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G01N 2800/205: Scaling palpular diseases, e.g. psoriasis, pytiriasis
- G01N 2800/50: Determining the risk of developing a disease
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the indications.

## Claims

### Claim 1

A method for treating an IL-18 associated disease or disorder in a population of subjects diagnosed of having abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject, or of having a predisposition to develop such a disease or disorder, comprising administering to said subject a therapeutically or prophylactically effective amount of an IL-18 inhibitor.

### Claim 2

A method for treating an IL-18 associated disease or disorder in a population of subjects diagnosed of having abnormal levels of free IL-18 and/or an abnormal ratio of free IL-18/IL-18 binding protein (IL-18BP) in the body fluids compared to the levels in the body fluids of a healthy control subject, or of having a predisposition to develop such a disease or disorder, comprising administering to said subject a therapeutically or prophylactically effective amount of an IL-18 inhibitor, wherein the level of free IL-18 in the body fluids of the subjects has been determined by an immunoassay.

### Claim 3 (depends on 2)

The method of claim 2, wherein the immunoassay comprises an IL-18BP or a functional equivalent or a functional part thereof as the capturing molecule.

### Claim 4 (depends on 3)

The method of claim 3, wherein the IL-18BP is a human IL-18BP (hIL-18BP).

### Claim 5 (depends on 4)

The method of claim 4, wherein the hIL-18BP is a recombinant hIL-18BP.

### Claim 6 (depends on 3)

The method of claim 3, wherein the IL-18BP is an isoform of IL-18BP.

### Claim 7 (depends on 1)

The method of claim 1, wherein the abnormal levels of free IL-18 and/or abnormal ratio of free IL-18/IL-18BP in the body fluids compared to the levels in the body fluids of a healthy control subject have been determined by a method comprising the steps of:
a) bringing a sample or a specific body part or body area suspected to contain free IL-18 into contact with the IL-18 binding molecule, which specifically binds to free IL-18, but not to IL-18 bound in a complex and functions as the capturing molecule for free IL-18;
b) allowing the IL-18 binding molecule to bind to free IL-18;
c) detecting the binding of IL-18 to the IL-18 binding molecule, and determining the amount of free IL-18 or the ratio of free IL-18/IL-18BP in the sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein said IL-18 associated disease or disorder is one selected from the group consisting of chronic obstructive pulmonary disease (COPD), transfusion-related lung injury, bronchopulmonary dysplasia (BPD), acute respiratory distress syndrome (ARDS), Adult Still's disease, juvenile Still's disease, interstitial lung disease (ILD), idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension, asthma, bronchiectasis, heart failure, amyotrophic lateral sclerosis (ALS), dry eye disease (DED), keratitis, corneal ulcer and abrasion, corneal neovascularization, pathological intraocular neovascularization, iritis, glaucoma, macular degeneration, Sjögren's syndrome, autoimmune uveitis, Behçet's disease, conjunctivitis, allergic conjunctivitis, dermatitis of eyelid, diabetes type 2, non-alcoholic fatty liver disease (NAFLD), steato hepatitis, solid organ and hematologic transplantation, ischemia reperfusion injury, familial Mediterranean fever, tumor necrosis factor receptor 1-associated periodic syndromes, cryopyrin-associated periodic fever syndromes, hyper-IgD syndromes, gout, Schnitzler syndrome, Wegener's granulomatosis also called granulomatosis with polyangitis (GPA), Hashimoto's thyroiditis, Crohn's disease, ulcerative colitis, immunoglobulin-4 (IgG4)-related diseases and stem cell therapies.

### Claim 9 (depends on 1)

The method of claim 1, wherein said IL-18 associated disease or disorder is an IL-18 induced systemic manifestation of inflammation and associated co-morbidities selected from the group consisting of emphysema, tissue inflammation, tissue destruction, lung resection, disappearance of the vasculature, apoptosis of endothelial cells, mucos metaplasia, cardiac hypertrophy, decrease of VEGF in the lung tissue, pulmonary vessel loss, vessel muscularization, vascular remodeling, collagen deposition, aberrant elastin layers in the lung, fibrotic airway remodeling, airspace enlargement, chronic remodeling of the airways and pulmonary vessels and decreased pulmonary function.

### Claim 10 (depends on 1)

The method of claim 1, wherein administration of the IL-18 inhibitor leads to modification, particularly inhibition, of increased expression of IFNγ, IL-13 or IL-17A in treated subjects compared to untreated subjects suffering from said disease or disorder.

### Claim 11 (depends on 1)

The method of claim 1, wherein said abnormal level of free IL-18 in the body fluids exceeds the level in body fluids of a healthy control subject by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%.

### Claim 12 (depends on 10)

The method of claim 10, wherein said abnormal levels of free IL-18 are elevated levels of free IL-18, such as ≥5 pg/mL and, particularly, up to 10000 pg/mL; and wherein the body fluid is serum.

### Claim 13 (depends on 1)

The method of claim 1, wherein the IL-18 inhibitor is an IL-18 binding protein (IL-18BP) or a functional equivalent or a functional part thereof.

### Claim 14 (depends on 13)

The method of claim 13, wherein the IL-18BP is a human IL-18BP (hIL-18BP).

### Claim 15 (depends on 14)

The method of claim 14, wherein the hIL-18BP is a recombinant human IL-18BP.

### Claim 16 (depends on 13)

The method of claim 13, wherein the IL-18BP is an isoform of IL-18BP.

### Claim 17 (depends on 2)

The method of claim 2, wherein the IL-18 inhibitor is an IL-18BP or a functional equivalent or a functional part thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the IL-18BP is hIL-18BP.

### Claim 19 (depends on 18)

The method of claim 18, wherein the hIL-18BP is a recombinant hIL-18BP.

### Claim 20 (depends on 17)

The method of claim 17, wherein the IL-18BP is an isoform of IL-18BP.

### Claim 21 (depends on 2)

The method of claim 2, wherein the level of free IL-18 in the body fluids of the subjects has not been determined by calculation based on, for example, the Law of Mass Action.
